Moreover, GIPR has not been the same focus of industry/academic efforts to produce antibodies, since GIPR agonism/antagonism has only just emerged as a viable option for diabetes/obesity therapy. The gene discussed is GIPR; the disease is obesity due to melanocortin 4 receptor deficiency.